Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin

William A. Banks, Andrew V Schally, Carlos M. Barrera, Melita B. Fasold, Debra A. Durham, Valer J. Csernus, Kate Groot, Abba J. Kastin

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Analogs of somatostatin are being investigated clinically for the treatment of various malignancies, including brain tumors. We studied the ability of three therapeutically promising radioactively labeled somatostatin octapeptide analogs, RC-160, RC-121, and RC-161, to cross the blood-brain barrier (BBB) after peripheral or central injection. After i.v. injection, intact RC-160 was recovered from the blood and the brain. The entry rates were different for each compound but were generally low. By contrast, entry across the intact BBB increased 220 times when RC-160 was given in a serum-free perfusate. This suggests that some serum-related factor, probably the previously described protein binding or an aggregation-promoting factor, is the main determinant in limiting the blood-to-brain passage of somatostatin analogs. Entry into the brain was not inhibited by the addition of unlabeled analog to the perfusate, showing that passage was probably by diffusion across the membranes that comprise the BBB rather than by saturable transport. By contrast, a saturable system was found to transport peptide out of the central nervous system (CNS). The clearance from the CNS of RC-160 and RC-121, but not RC-161, was faster than could be accounted for by reabsorption of cerebrospinal fluid. Transport of radioactively labeled RC-160 out of the CNS was inhibited by unlabeled RC-160 or somatostatin but was not affected by some other peptides known to cross the BBB by their own transport systems. More than 80% of the radioactivity recovered from the blood after intracerebroventricular injection of RC-160 was eluted by HPLC at the position of the labeled analog, showing that the peptide had crossed the BBB in intact form. Our results indicate the presence of a saturable transport system in one direction across the BBB for some superactive analogs of somatostatin.

Original languageEnglish
Pages (from-to)6762-6766
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume87
Issue number17
StatePublished - Sep 1 1990
Externally publishedYes

Fingerprint

Somatostatin
Blood-Brain Barrier
Permeability
Central Nervous System
Peptides
Injections
Brain
vapreotide
Serum
Protein Binding
Brain Neoplasms
Radioactivity
Cerebrospinal Fluid
High Pressure Liquid Chromatography
Membranes
Neoplasms

Keywords

  • Cancer
  • Carrier-mediated
  • Central nervous system
  • Peptides
  • Transport

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Banks, W. A., Schally, A. V., Barrera, C. M., Fasold, M. B., Durham, D. A., Csernus, V. J., ... Kastin, A. J. (1990). Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin. Proceedings of the National Academy of Sciences of the United States of America, 87(17), 6762-6766.

Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin. / Banks, William A.; Schally, Andrew V; Barrera, Carlos M.; Fasold, Melita B.; Durham, Debra A.; Csernus, Valer J.; Groot, Kate; Kastin, Abba J.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 87, No. 17, 01.09.1990, p. 6762-6766.

Research output: Contribution to journalArticle

Banks, WA, Schally, AV, Barrera, CM, Fasold, MB, Durham, DA, Csernus, VJ, Groot, K & Kastin, AJ 1990, 'Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin', Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 17, pp. 6762-6766.
Banks, William A. ; Schally, Andrew V ; Barrera, Carlos M. ; Fasold, Melita B. ; Durham, Debra A. ; Csernus, Valer J. ; Groot, Kate ; Kastin, Abba J. / Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin. In: Proceedings of the National Academy of Sciences of the United States of America. 1990 ; Vol. 87, No. 17. pp. 6762-6766.
@article{d777c35f445d4e4f9184d75454f663be,
title = "Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin",
abstract = "Analogs of somatostatin are being investigated clinically for the treatment of various malignancies, including brain tumors. We studied the ability of three therapeutically promising radioactively labeled somatostatin octapeptide analogs, RC-160, RC-121, and RC-161, to cross the blood-brain barrier (BBB) after peripheral or central injection. After i.v. injection, intact RC-160 was recovered from the blood and the brain. The entry rates were different for each compound but were generally low. By contrast, entry across the intact BBB increased 220 times when RC-160 was given in a serum-free perfusate. This suggests that some serum-related factor, probably the previously described protein binding or an aggregation-promoting factor, is the main determinant in limiting the blood-to-brain passage of somatostatin analogs. Entry into the brain was not inhibited by the addition of unlabeled analog to the perfusate, showing that passage was probably by diffusion across the membranes that comprise the BBB rather than by saturable transport. By contrast, a saturable system was found to transport peptide out of the central nervous system (CNS). The clearance from the CNS of RC-160 and RC-121, but not RC-161, was faster than could be accounted for by reabsorption of cerebrospinal fluid. Transport of radioactively labeled RC-160 out of the CNS was inhibited by unlabeled RC-160 or somatostatin but was not affected by some other peptides known to cross the BBB by their own transport systems. More than 80{\%} of the radioactivity recovered from the blood after intracerebroventricular injection of RC-160 was eluted by HPLC at the position of the labeled analog, showing that the peptide had crossed the BBB in intact form. Our results indicate the presence of a saturable transport system in one direction across the BBB for some superactive analogs of somatostatin.",
keywords = "Cancer, Carrier-mediated, Central nervous system, Peptides, Transport",
author = "Banks, {William A.} and Schally, {Andrew V} and Barrera, {Carlos M.} and Fasold, {Melita B.} and Durham, {Debra A.} and Csernus, {Valer J.} and Kate Groot and Kastin, {Abba J.}",
year = "1990",
month = "9",
day = "1",
language = "English",
volume = "87",
pages = "6762--6766",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "17",

}

TY - JOUR

T1 - Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin

AU - Banks, William A.

AU - Schally, Andrew V

AU - Barrera, Carlos M.

AU - Fasold, Melita B.

AU - Durham, Debra A.

AU - Csernus, Valer J.

AU - Groot, Kate

AU - Kastin, Abba J.

PY - 1990/9/1

Y1 - 1990/9/1

N2 - Analogs of somatostatin are being investigated clinically for the treatment of various malignancies, including brain tumors. We studied the ability of three therapeutically promising radioactively labeled somatostatin octapeptide analogs, RC-160, RC-121, and RC-161, to cross the blood-brain barrier (BBB) after peripheral or central injection. After i.v. injection, intact RC-160 was recovered from the blood and the brain. The entry rates were different for each compound but were generally low. By contrast, entry across the intact BBB increased 220 times when RC-160 was given in a serum-free perfusate. This suggests that some serum-related factor, probably the previously described protein binding or an aggregation-promoting factor, is the main determinant in limiting the blood-to-brain passage of somatostatin analogs. Entry into the brain was not inhibited by the addition of unlabeled analog to the perfusate, showing that passage was probably by diffusion across the membranes that comprise the BBB rather than by saturable transport. By contrast, a saturable system was found to transport peptide out of the central nervous system (CNS). The clearance from the CNS of RC-160 and RC-121, but not RC-161, was faster than could be accounted for by reabsorption of cerebrospinal fluid. Transport of radioactively labeled RC-160 out of the CNS was inhibited by unlabeled RC-160 or somatostatin but was not affected by some other peptides known to cross the BBB by their own transport systems. More than 80% of the radioactivity recovered from the blood after intracerebroventricular injection of RC-160 was eluted by HPLC at the position of the labeled analog, showing that the peptide had crossed the BBB in intact form. Our results indicate the presence of a saturable transport system in one direction across the BBB for some superactive analogs of somatostatin.

AB - Analogs of somatostatin are being investigated clinically for the treatment of various malignancies, including brain tumors. We studied the ability of three therapeutically promising radioactively labeled somatostatin octapeptide analogs, RC-160, RC-121, and RC-161, to cross the blood-brain barrier (BBB) after peripheral or central injection. After i.v. injection, intact RC-160 was recovered from the blood and the brain. The entry rates were different for each compound but were generally low. By contrast, entry across the intact BBB increased 220 times when RC-160 was given in a serum-free perfusate. This suggests that some serum-related factor, probably the previously described protein binding or an aggregation-promoting factor, is the main determinant in limiting the blood-to-brain passage of somatostatin analogs. Entry into the brain was not inhibited by the addition of unlabeled analog to the perfusate, showing that passage was probably by diffusion across the membranes that comprise the BBB rather than by saturable transport. By contrast, a saturable system was found to transport peptide out of the central nervous system (CNS). The clearance from the CNS of RC-160 and RC-121, but not RC-161, was faster than could be accounted for by reabsorption of cerebrospinal fluid. Transport of radioactively labeled RC-160 out of the CNS was inhibited by unlabeled RC-160 or somatostatin but was not affected by some other peptides known to cross the BBB by their own transport systems. More than 80% of the radioactivity recovered from the blood after intracerebroventricular injection of RC-160 was eluted by HPLC at the position of the labeled analog, showing that the peptide had crossed the BBB in intact form. Our results indicate the presence of a saturable transport system in one direction across the BBB for some superactive analogs of somatostatin.

KW - Cancer

KW - Carrier-mediated

KW - Central nervous system

KW - Peptides

KW - Transport

UR - http://www.scopus.com/inward/record.url?scp=0025043917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025043917&partnerID=8YFLogxK

M3 - Article

C2 - 1975697

AN - SCOPUS:0025043917

VL - 87

SP - 6762

EP - 6766

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 17

ER -